Medication for brain cell protection

FIELD: medicine.

SUBSTANCE: invention relates to pharmacology. Medication for brain cell protection contains dominant protein extract from placenta tissue, obtained by chromatographic separation of protein fraction of 8-10 components with total molecular weight from 15 to 200 kDa, 70-80% of fraction consisting of protein with molecular weight about 70 kDa. In order to obtain said medication powdered placenta is extracted by means of alkalescent buffer in presence of inhibitors of proteolytic protein cleavage and centrifuged. Centrifugate is passed through chromatographic column with anion-exchange carriers balanced by means of the same buffer, column is washed from unbound material, proteins are eluted with neutral salt solution. Collected material is diluted with water bringing pH to subacid value and diluted substrate is successively passed through column with anion-exchange carrier and column with cation-exchange carrier, balanced with buffer solutions to pH about 6.0. Final product is obtained after sterilisation.

EFFECT: method application allows to obtain efficient medication of high purity, normalising nervous system functions.

3 cl, 1 tbl, 4 ex

 

The invention relates to the field of pharmacology and is a means to protect brain cells from ischemic and other damage and the method of its production from placental tissue. Stated the tool could be used in medicine as a means of normalizing the function of the nervous system.

Ischemic stroke is one of the most frequent manifestations of vascular disease of man, one of the main causes of death or persistent disability in persons aged 55 years. The frequency of deaths reaches 20-30%and 30-40% of cases the outcome of ischemic stroke is profound disability resulting from apoptotic death of large populations of brain neurons, accompanied by pronounced mental and/or motor function (Eyisi and others, 1998-2000).

The lack of significant progress in the treatment of ischemic stroke, despite sufficient clarity of its main pathophysiological mechanisms, indicates a lack of effectiveness of existing tools and methods for the prevention and treatment of this pathology and stimulates the experimental search for new more effective drugs.

Known methods for producing biologically active substances and medicinal products from animal raw materials (patent RF №944191, 1994; A.S. SU # 1112606, 1996; A.S. SU # 1218521, 1994; A. SU # 1227198, 1986; RF patent №1448443, 1994; RF patent №1522486, 1993; RF patent №2075944, 1997; RF patent №2161501, 2001; US patent 4341765, patent GB 1161896, 1969; patent FR 2583982, 1987).

A known method of producing a drug that has healing activity in violation of the functions of the brain (patent RF №1298979, 1993), which allows you to select from cortex slaughtered animals biologically active peptides that have a positive effect on nerve function. This drug is produced by processing the original raw material (gray matter of the cerebral hemispheres) acetone at t=-10°C...-4°C and the ratio of brain tissue and acetone 1:5 for 18...30 hours, homogenizing, extracting the homogenate 2...4% solution of acetic acid for 48...72 hours at pH 3.5...4.5 in the presence of zinc chloride at a concentration of 0.6 to 2 g/l and the ratio of the homogenate and solution of acetic acid 1:(8...4), centrifugation, precipitation of the biologically active substances acetone at t=-3°...-5°C and the ratio of supernatant and acetone 1:(7...5), and ion-exchange chromatography of the resulting sludge on the cation exchanger "Bicarb". In the ion-exchange chromatography receive a fraction containing predominantly alkaline polypeptides with a molecular mass of from 2000 to 6000 Da.

It should be noted that the method described in the patent of Russian Federation №1298979, it is not possible to extract from cortex acidic and neutral is performance communications polypeptides, and to purify the resulting product from impurities, and the resulting end product has a relatively low therapeutic efficacy.

In practice, the treatment of ischemic stroke currently widely used drug "Cerebrolysin" (""", Austria), which is a heterogeneous mixture of peptides and amino acids derived from the brain of pigs by standardized enzymatic processing (Cerebrolysin: pharmacological effects and place in clinical practice. Sat. reports of the 6th International Symposium, Moscow, 2002). Established that the product of biological origin has a certain level of neurotrophic activity and inhibits apoptosis of neurons subjected to various adverse effects. At the same time, the fact of the unresolved problems of prevention and treatment of ischemic stroke indicates a lack of efficacy of Cerebrolysin (as well as any other applicable today nootropics and neuroprotective agents of biological origin or chemically synthesized) and determines the need for the development and implementation of new, more effective drugs.

The effectiveness of the drug "Cerebrolysin" appears when it is used in doses of 4-10 mg/kg by daily parenteral administration within 7-10 days posleoperatsionnogo stroke. This drug tends to reduce the frequency of deaths and a reduction in the frequency of cases of severe disability compared with patients receiving placebo (Whiskerton. Cerebrolysin in the treatment of acute ischemic stroke. Cerebrolysin: pharmacological effects and place in clinical practice. Sat. reports of the 6th International Symposium, Moscow, 2002, 28-35).

Understanding the biological basis of the pathological process indicates that progress in treatment can be achieved on the search paths and the implementation of more active neurotrophic and neuroprotective drugs. It is known that the source of a number of trophic factors is the placenta, which provides and supports rapid growth and accelerated development of the nervous tissue and other organs and tissues of the developing fetus.

From the publication of the application for patent of the RF No. 2007 118245 known peptide placenta extract, containing 5.0-35.0 mg/ml protein, 2.0-5.0 mg/ml of glycoproteins and 0.5-1.0 mg/ml of Triton X100, and its production method based on the extraction of biological material - the placenta, which are crushed, pour phosphate buffer with the addition of Triton, and then she by centrifugation allocate the extract is then cleaned from impurities.

Also from the publication of the application for patent of the RF No. 004130760 And from 10.04.2006 known means, possessing neuroprotective and nootropic activity containing proteins, obtained by extraction of the placenta alkaline buffer. This publication describes how to obtain this tool by grinding the human placenta, slightly alkaline extraction buffer, centrifugation, chromatography was carried out of centrifugate with anion exchange media and equilibrated with the same buffer, laundering chromatographic column from unbound material with subsequent elution of proteins by sodium chloride solution and sterilized by filtering through antimicrobial filters.

This way, in principle, under laboratory conditions to obtain such as the target product, in practice on an industrial scale was not possible to identify the finished product of the desired purity, devoid of ballast impurities protein nature.

The objective of the proposed technical solution is an effective means of normalizing the function of the nervous system, high purity acceptable on an industrial scale method.

The solution of the problem serves as a means to protect brain cells from ischemic and other damages, containing the dominant protein extract of placenta tissue with getting through chromatographic separation of protein fractions from 8-10 components with a total of molecule the Noah weighing from 15 to 200 kDa, and 70-80% fraction accounts for a protein with a molecular mass of about 70 kDa, and 20-30% fraction are proteins with a molecular mass of from 15 to 60 kDa and 100 to 200 kDa.

To receive funds in accordance with the task step gel filtration was replaced by an additional (final) stage of the combined ion-exchange chromatography. Namely, the primary eluate containing the product NP-3, 3-fold diluted with distilled water to reduce the concentration of NaCl, brought the pH of the solution to 6.0, and then the resulting solution was passed through two columns connected in series with anion-exchange and cation exchange media. The volume of the media were taken at a rate of 1 ml gel 50 mg of total protein solution. The solution passed through both ion-exchange column without binding media contained the purified product NP-3, whereas the impurity ballast products was associated with anion-exchange or cation-exchange media.

Thus, the method of obtaining funds is that crushed the placenta is extracted slaveselect buffer in the presence of inhibitors of proteolytic cleavage of proteins, centrifuged, centrifugal passed through the chromatographic column with anion-exchange medium, equilibrated with the same buffer, washed column from unbound material, elute Bel and the solution of a neutral salt the collected material was diluted with water to bring the pH to slightly acidic values and ignore the diluted substrate sequentially through a column of anion exchange media and a column of cation exchange media, offset buffer solutions with a low concentration of salts and pH of about 6.0, after sterilization receive the finished product. The solution passed through both ion-exchange column without binding media contained the purified product (NP-3), while the impurity ballast products was associated with anion-exchange or cation-exchange carriers. The finished product (NP-3) represented a protein fraction, consisting of 8-10 components with a total molecular mass of from 15 to 200 kDa, and 70-80% fraction accounts for a protein with a molecular mass of about 70 kDa, and had the ability to protect brain cells from ischemic and other damage.

Primer

Obtaining the drug NP-3

Fresh preparation of the placenta is extracted with alkaline buffer (e.g., 0.01 M Tris-HCl, pH 8 in the presence of the most common inhibitors of proteolytic cleavage of proteins), centrifuged and passed through a chromatographic column filled with anion-exchange media (e.g., DEAE-cellulose), equilibrated with the same buffer.

Washed column from unbound material 0.05 M solution of a neutral salt, e.g. the, 0.05 M of NaCl on the source buffer without inhibitors of proteolysis.

Elute the fraction of the target product by passing through a column of 0.15 M NaCl solution. Collect the protein peak.

The resulting material was 3-fold diluted with distilled water, adjusted pH to 6.0 and passed through two series-connected column with anion-exchange and cation-exchange carriers (for example, DEAE-cellulose and cm-cellulose), balanced 0.01 M buffer solutions with pH 6.0. The volume of the media were taken at a rate of 1 ml gel 50 mg of total protein solution. The solution passed through both ion-exchange column without binding media contained the purified product NP-3, whereas the impurity ballast products was associated with anion-exchange or cation-exchange carriers, which could be regenerated by standard protocols and used multiple times.

The collected material is sterilized (for example, by filtration through amicrobic filters), measure the concentration of a protein (for example, by the method of Lowry), Packed and stored until use at -40°C.

The resulting product has the following characteristics:

A) According to electrophoresis in 10% polyacrylamide gel in the presence of sodium dodecyl sulfate and dithiothreitol): protein fraction, consisting of 8-10 related components with a total molecular mass of from 15 to 200 kDa and 70-80% fraction accounts for a protein with a molecular mass of about 70 kDa.

B) the Main protein component fraction, which accounts for 70-80% of the total protein, immunohistochemistry (using enzyme-linked immunosorbent assay and Western blot turns) was identified as alpha-fetoprotein.

(Alpha-fetoprotein (AFP) is described, in particular, the dissertation Shurginov (Perm - 2003). AFP is a glycoprotein with a molecular mass 69000 daltons, consisting of a single polypeptide chain consisting of about 600 amino acids and containing about 4% carbohydrates. It is part of the genetic family albuminoidal located at the person in the 4th chromosome. We have investigated the efficiency of the use of AFP in the practice of therapy of the following diseases:

- pneumoconiosis;

- bronchial asthma;

- infiltrative pulmonary tuberculosis;

- autoimmune thyroiditis;

- chronic hepatitis and liver cirrhosis).

B) the Output of the active substance (drug NP-3)isolated from the tissues of the placenta)is not less than 100 mg per 1 kg of raw material.

G) a Purified, sterile filtered and bottled product, sent to storage, is a pinkish clear solution with a concentration of total protein 1 mg/ml

Experimental verification showed that the proposed solution provides maximum biological stability of therapeutic efficacy of the drug, normalizing the function of brain cells, which is confirmed by the results of the experiments presented in the examples illustrating the invention.

In experiments on laboratory animals revealed the following.

Example 2.

The study of possible progenote drug

The study was conducted on adult outbred rabbits male weighing 2.5-3 kg standard method (GF XI, issue 2, .183) when the test dose of 0.25 mg per 1 kg of weight of the animal in 1.0 ml of isotonic 0.9% sodium chloride for injection.

It is shown that the introduction of the drug was not accompanied by a rise in body temperature, i.e. the agent has no pyrogenic properties.

Example 3.

Study the possible toxicity of the drug.

A) General toxic effect of the drug was investigated in accordance with the requirements of the "Manual on experimental (preclinical) study of new pharmacological substances" (2000): acute toxicity after a single dose of the drug, as well as subacute and chronic toxicity with long-term administration of the drug.

B) study on the acute toxicity was carried out on outbred mice-males weighing 20-24, Animals were randomly divided into groups of 5 mice. The drug was administered to the animals once intramuscularly in doses of 25 mg/kg 50 mg/kg 100 mg/kg and 200 mg/kg is 0.25 ml of sterile 0.9% NaCl solution. Animals of the control group in the same volume was injected with 0.9% NaCl solution.

B) the Study of subacute toxicity was carried out on outbred rats-males weighing 150-200 g, randomly divided into groups of 5 animals. The drug was administered intramuscularly daily for 90 days at doses of 1 mg/kg, 10 mg/kg, 100 mg/kg in 0.5 ml of sterile 0.9% NaCl solution. Animals of the control group were injected in the same volume of sterile 0.9% NaCl solution. Before drug administration, at 30, 60 and 90 days after the start of a drug in animals have investigated the morphological composition of peripheral blood. Statistically significant differences between the studied parameters in the control and experimental groups were not identified (p>0.1).

D) study of the chronic toxicity was carried out for 6 months on white outbred rats male weighing 150-200 g randomly divided into groups of 5 animals. Animals of the experimental groups received daily drug intramuscularly for 6 months. in doses of 1 mg/kg, 10 mg/kg, 100 mg/kg in 0.5 ml of sterile 0.9% NaCl solution. Animals of the control group were injected according to the same scheme of sterile 0.9% NaCl solution in the same volume. Before drug administration, at 90 days and 180 days after the start of a drug in animals have investigated the morphological composition of peripheral blood, the velocity of the erythrocyte sedimentation (ESR) and the total protein content in serum by the method of Lowry. After completion of the experiment conducted pathomorphological study of the brain and spinal cord, thyroid gland, adrenal glands, testes, pituitary gland, heart, lung, aorta, liver, kidney, pancreas, stomach, small intestine, colon, thymus and spleen. Statistically significant differences between the studied parameters in the control and experimental groups were not identified (p>0.07).

Thus, it was shown that the introduction of the drug in all used doses were not toxic reactions, which testifies to the great therapeutic breadth dosages of the drug.

Example 4. Experimental use of the drug (the description of these techniques see (Poletaev AV, Arapov N.A. Pharmacologyonline, 2006, 3, 73-79. (http://www.unisa.it/download/196614518051168815.Poletaev.pdf)

1. Laboratory adult rats were trained labyrinth behavior with positive food reinforcement in a Morris water maze by standard methods.

2. Laboratory adult rats were trained to conduct passive avoidance darkened compartment with electrovalves reinforcement by standard methods.

3. Laboratory adult rats tested on the behavior in the "open field" by standard methods.

4. Produced bilateral 30-minute ligation of both carotid arteries at the level of the upper cervical by standard methods.

5. 3 hours later after model insufficiency brain animals intraperitoneally once injected drug NP-3 at a dose of 0.2 mg/kg of body weight or Cerebrolysin in the dose of 10 mg/kg (active control).

6. After 7 days was assessed level of General motor and orienting-exploratory activity of animals and the level of play they have previously developed skills (comparison group: 1. rats after acute cerebral ischemia treated with Cerebrolysin, 2. rats after acute cerebral ischemia treated with the drug NP-3, 3. rat passive control not exposed insufficiency).

The influence of the drug NP-3 on the survival and function of the nervous system in rats exposed insufficiency brain (Poletaev AV, Arapov N.A. Pharmacologyonline, 2006, 3, 73-79. (http://www.unisa.it/download/196614518051168815.Poletaev.pdf)

Table

Mortality after acute ischemia of the brainThe average level of locomotor activity in groups (points)Play labyrinth skills (intermediate level groups)Play skills passive avoidance (Average for groups of animals)
1. Rats groups control (n=20)18% 24%44%
2. Rats treated with NP-3 (n=20)10%4877%∗∗85%
3. Rats not subjected to ischemia of the brain (n=12)0%5292%97%
The confidence levels of the differences:*- p<0.05,**- p<0.01

Provides for the introduction of the drug into the body in the form of a nasal drip infusion (1 drop in each nostril)daily for 12-14 days, although it is possible and intravenous or intralumenal the introduction of the drug with the appropriate recalculation of the dosages.

1. Tool for protecting brain cells containing the dominant protein extract from placental tissue obtained by chromatographic separation of the protein fraction from 8-10 components with a total molecular mass of from 15 to 200 kDa, and 70-80% fraction accounts for a protein with a molecular mass of about 70 kDa.

2. The tool according to claim 1, characterized in that 20-30% faction to have protein with a molecular mass of from 15 to 60 kDa and 100 to 200 kDa.

3. The method of obtaining media is tion to protect brain cells according to claim 1, namely, that crushed the placenta is extracted with alkaline buffer in the presence of inhibitors of proteolytic cleavage of proteins, centrifuged, centrifugal passed through the chromatographic column with anion-exchange medium, equilibrated with the same buffer, washed column from unbound material, elute proteins with a solution of a neutral salt, the collected material is diluted with water to bring the pH to slightly acidic values and ignore the diluted substrate sequentially through a column of anion exchange media and a column of cation exchange media, balanced buffer solution to a pH of about 6.0, after sterilization receive the finished product.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to surgery. Blood is sampled from cubital vein in patients with acute pancreatitis on 1-3 and 7-10 day from disease beginning. Level of blood serum myoglobin is determined by method of performing reaction of passive hemagglutination. If level of blood serum myoglobin on 1-3 day increase from 95 to 128 ng/ml, acute fatty pancreatic necrosis is diagnosed, if myoglobin level in blood serum is higher than 128 ng/ml, hemorrhagic pancreatic necrosis is diagnosed, and if level of myoglobin in blood serum on 7-10 day increases higher than 256 ng/ml, hemorrhagic pancreatic necrosis in stage of infection of pancreatic necrosis nidus is diagnosed.

EFFECT: method allows to correct drug therapy and individually ground tactics of treating patients with acute pancreatitis depending on severity of disease form and presence of infection.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: there is offered an arteriosclerosis diagnostic technique based on the detection of various combinations of specific polypeptide markers. To detect the presence or absence of polypeptide marker, capillary electrophoresis, gaseous-phase ion spectrometry and/or mass spectrometry are used.

EFFECT: method allows early high-probability minimally invasive arteriosclerosis detection.

13 cl, 1 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to leprology, and can be used particularly for the detection of specific liver disease in the leprosy patients. Blood serum of the leprosy patients is analysed to determine the level of US-M.leprae and DIS-BSA leprosy mycobacteria antigen antibodies, and also the concentration of alpha-1-antitrypsin. If observing the level of antibodies to two antigens increased as compared to a norm and the concentration of alpha-1-antitrypsin increased higher than 346.7 mg/dl, liver disease is detected in the leprosy patients.

EFFECT: method provides higher accuracy.

4 ex

FIELD: medicine.

SUBSTANCE: essence of invention includes selection of sample for testing from area of malignant affection in patient, suffering from cancer of large intestine, selection of control sample, measurement of the level of one or several genetic markers, selected from the group, comparison of measured levels in experimental samples with control ones. Reducing of levels of one or several genetic markers in comparison with control sample, indicates increased resistance to docetaxel. Also described are sets which allow to predict or realise monitoring of patient's response to docetaxel.

EFFECT: identification of genetic markers, by which it is possible to realise patient's response to chemical therapy by docetaxel.

18 cl, 9 ex, 3 tbl, 16 dwg

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention relates to molecular biology and can be used in designing agent and methods of modulating body functions associated with HGF/c-met signalling pathway. The invention discloses HGF/c-met polypeptide-antagonists which are mutant forms of HGF which contain a mutation in the N-terminal part of the β-chain and/or in its dimerisation part. The disclosed polypeptides have lower biological activity compared to wild type HGG and can be used in modulating activity of c-met, cell proliferation, cell migration and angiogenic cell activity.

EFFECT: invention describes a method of obtaining HGF muteins using DNA recombinant technology and agents which are necessary for its existence.

22 cl, 8 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: in order to predict insufficiency of saturation with oxygen of peripheral blood of pregnant women who have herpes-virus infection, content of glucose-6-phosphat-dehydrogenase and TNFα in peripheral blood is determined. Discriminant equation D=-0.589·G-6-PDG+{+1.23·TNFα} is solved. If value of discriminant function is equal or greater than 89.95, predicted is development of oxygen insufficiency, accompanied with reduction in peripheral blood of pregnant women of pO2 with titre of antibodies to Herpes simplex virus 1:12800 to 27.63±0.7 mm Hg, and of HbO2 to 90.2±0.47% (control: pO2 - 39.22±0.5 mm Hg; HbO2 - 95.3±0.27%).

EFFECT: increased accuracy of determining possibility of development of oxygen insufficiency in pregnant woman with herpes-virus infection.

3 tbl

FIELD: medicine.

SUBSTANCE: in estimation of local inflammation activity in case of background diseases of neck of uterus sampling of analysed biomaterial is performed by bringing of device for native material removal to external neck of uterus fauces. Said device has elongated holder in form of rod with length, exceeding length of vagina. From distal side of rod, at angle to it, located is operation element in form of roller. Proximal end of rod serves as manipulator-handle. Sampled material is placed until complete submergence into tightly closable test tube, filled with 1.0 ml of 0.155 M solution of sodium chloride. Mixture is centrifuged for 10 minutes. Obtained materials are analysed by method of solid phase ELISA analysis on boards by means of set of reagents "Vector-Best". Concentration of cytokine of interleukin-6 in analysed samples is determined spectrophotometrically. If value is higher than 50 pg/ml to 92 pg/ml, conclusion about presence of chronic inflammation process is made. If value is higher than 92 pg/ml, conclusion about active course of inflammatory process and expressed immune response is made.

EFFECT: application of method allows to increase quality of analysed native material and accuracy of obtained result without complicating analysis process.

2 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention can be used for diagnostics of presence of destructive process in uterine appendages in case of localised peritonitis if gynecological genesis, and for selection of optimal treatment tactics. In order to realise the method content of C-reactive protein (CRP) in blood serum is determined by turbodimetric method, if values of C-reactive protein content are 130 mg/l and higher, purulent-destructive process in uterine appendages in case of localised peritonitis is diagnosed, if values of C-reactive protein content are lower than 130 mg/l diagnosed is purulent salpingitis in case of pelvioperitonitis.

EFFECT: application of method allows to detect presence of purulent-destructive process in uterine appendages in case of pelvioperitonitis in urgent way, which determines tactics of further treatment.

2 ex

FIELD: medicine.

SUBSTANCE: invention can be used for obtaining diagnostic and/or therapeutic agents, in particular antibodies, which specifically interact with proteins of cell surface of target cells. Claimed is method of screening phage display library and including it method of isolation of library element, which is specific partner of binding of target cell surface protein, and method of isolation of unknown cell surface protein, specifically interacting with library element. Method of screening phage display library according to invention includes contact of said library with cells of interest with further separation of cells, which bound with one or several elements of expression library, from non-bound elements by separation through organic phase, and differs by introduction of additional stage, which consists in carrying out before said separation of at least one stage of material washing, and ensures essential increase of method efficiency.

EFFECT: higher efficiency.

30 cl, 7 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology, can be used for prediction of progression of myopia acquired in schools in 10-14 and 15-17 year old children. Blood serum is analysed for cartilage glycoprotein-39 with the use of sandwich-type enzyme immunoassay. If its concentration is within 34.7-53.4 ng/ml in 10-14-year-old children and 22-56.3 ng/ml in 15-17-year-old children, a permanent course of myopia is predicted. The concentration 18.5-33.9 ng/ml in 10-14-year-old children and 53.7-69 ng/ml in 15-17-year-old children enables to predict a progressive course of myopia.

EFFECT: use of the invention improves accuracy of the prediction of clinical course.

4 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves three intramuscular introduction of ferroglucin by 75 mg (1 ml) every 6 days, three intramuscular introduction of phosprenyl by different syringes in different points simultaneously with an iron preparation, 0.10 ml/kg for the first injection, 0.08 ml/kg for the second injection, 0.07 ml/kg for the third injection, and the intramuscular injections of gamavit 0.017 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows normalising the level of spontaneous thrombocyte aggregation, helps to avoid vascular complications in newborn piglets with anaemia, to optimise microcirculation and tissue tropism, to accelerate growth of animals, to improve a herd, to provide higher quality and amount of produced meat, to produce a healthy posterity.

1 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves the introduction of 1% novocaine, denatured emulsified placenta, nettle tincture and Endometromag T. 10 minutes after foetus birth, 1% novocaine is introduced in dosage 100 ml with puncture procaine block assistance, and for the 6th day after calving, novocaine is introduced once again in the same dose; denatured emulsified placenta is introduced suncutaneously in dosage 20 ml immediately after calving and 72 hours after calving; nettle tincture prepared by covering nettle with boiling water in the ratio 1:20 is introduced in dosage 5 l for the first days and for the next 3 days running, and Endometramag T is administered intrauterinally on the first days after calving in dosage 100 ml.

EFFECT: method is effective in the prevention of postnatal subinvolution of uterus in cows, allows accelerating lochia elimination from uterus to be prepared for a new pregnancy.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary. Method of obtaining placental medication on the basis of cows' placenta is characterised by the following: in period of evisceration of incalvers at slaughterhouse, pregnant uterus is removed in the first half of pregnancy (4-5 months), non-separated caruncles and cotyledons are collected from baby's and maternal placenta by cutting cotyledons with curved sterile scissors from baby's placenta, which is made through longitudinal cut in serous-muscular-mucous layer of pregnant uterine horn, puncturing with a needle chorionically amniotic membrane by vacuuming amniotic fluid is collected from amniotic bubble; cut off cotyledond are crushed with caruncles by cutting, after that in mechanical homogeniser, amniotic fluid, previously collected from the same uterus, is added in amount 10:1 of homogenous mass, slowly mixed and settled, after that centrifuged at 10 thousand rev/min for 10 minutes, conservation is performed, supernatant part is poured into vials and sealed.

EFFECT: invention ensures increase of preparation efficiency.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to veterinary. Method of obtaining biologically active tissue preparation based on cows' placenta includes filtration, crushing, homogenisation, centrifugation, pregnant uterus being removed in the first half of pregnancy (4-5 months) in period of evisceration of incalvers at slaughterhouse, longitudinal cut of serous-muscular-mucous layer of pregnant uterine horn is performed, cotyledons are collected by removing them from caruncles, preserving integrity of villi, cutting cotyledons with curved sterile scissors from tissue of baby placenta, puncturing with a needle chorionically amniotic membrane by vacuuming amniotic fluid is collected from amniotic bubble, cut cotyledons are crushed by cutting, and after that in homogeniser, earlier collected from the same uterus amniotic fluid is added in amount 10:1 of homogeneous mass, mixed slowly and settled, after that centrifuged at 10 thousand rev/min for 10 minutes, conservation is performed, supernatant part is poured into vials and sealed.

EFFECT: invention ensures increase of preparation efficiency.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to experimental medicine, namely to therapy of radiation sickness of laboratory animals, and deals with restoration of myeloid tissue after exposure to ionising irradiation. For this purpose one hour after irradiation intravenous allogenic transplantation of multipotent mesenchymal stromal cells, separated from placenta, in quantity of 6×106 cells/kg is carried out.

EFFECT: such regimen of transplant introduction insures efficient restoration of myeloid tissue of old laboratory animals and allows to extend arsenal of means for anti-radiation therapy.

5 tbl

FIELD: veterinary science.

SUBSTANCE: invention relates to veterinary medicine and is to be utilised for prophylactics and treatment of cow reproductive malfunctions. The method envisages cow placenta preparation. The prepared cow placenta is chilled. Then the placenta having been chilled is homogenised and exposed to microwave radiation at a frequency of 2450±50 MHz, with the raw material heated to a temperature of no more than +60°C. Then the resultant liquid is mixed with distilled water at a ratio of 1:4 and boiled during 10 minutes. Then the resultant liquid is chilled, centrifuged and filtered. Then the resultant liquid is mixed with Fraction 2 Dorogov antiseptic stimulant, bringing the concentration of Fraction 2 Dorogov antiseptic stimulant to 4% of the total liquid volume; after that one adds a 20% alcoholic solution of thymol in an amount of 0.1% of the total liquid volume. Then the resultant preparation is autoclaved.

EFFECT: proposed invention enables improvement of cow impregnation capacity after initial insemination.

1 tbl, 2 ex

FIELD: pharmacology.

SUBSTANCE: invention refers to medicine, veterinary science and agriculture. There is presented exogenous modulator of metabolic and energy interchange processes between a cell and environment representing a polypeptide metabolic process modulator of molecular weight 15 to 10 KDa made of human placenta by chemical modification of placental biobased products with reactions of chlorination, oxidation, hydrolysis, and containing covalently bound chlorine atoms with nitrogen atoms of peptide bond in amount 0.5 to 40% of weight of an end product. There is also offered method for making said modulator.

EFFECT: correction and regulation of metabolic processes to ensure maximum viability of human body, animals and plants.

7 cl, 8 tbl, 10 ex

FIELD: veterinary.

SUBSTANCE: method consists in introducing of mesenchymal stem cells of umbilical cord or placenta, taken after normal childbirth. Endolymphatic introduction of cells is performed by injections of 1-2 ml of physiological solution, which contains 0.075-0.20×106 cells/kg of weight along spine or leg in single-step1-2 times per year.

EFFECT: method allows to improve animal's condition, increasing of its activity, normalises metabolism.

1 ex

FIELD: veterinary.

SUBSTANCE: method consists in introduction of mesenchymal solution of stem cells from umbilical cord or placenta with concentration 0.05-0.250×106 cells/kg of animal weight. At the same time phased hypodermic introduction of one part of stem cells solution in area of metatarsus, tarsus, and saltatory joint of hind legs and two parts of solution in area of sacrum and along lumbar spine is carried out.

EFFECT: method allows increasing of treatment of dog's paralysis and epilepsy, as result of post infection genesis.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and namely to urology and deals with treatment of benign hyperplasia of prostate gland. For that purpose 70 ml of 1% placenta hydrolyzate with temperature of 37°C is injected into the rectum of the patient lying on his one side with legs bent in hip joints. Then radiation head with a restrictor of Sterzhen -1 device is introduced into the rectum, and ultrasound action with intensity of 0.3±0.05 W/cm is performed in pulse mode. Effective radiation area is 2cm2 ±10%, pulse frequency is 50 Hz. Duration time of daily procedures is 6 minutes; treatment course consists of 8 procedures.

EFFECT: method provides stimulation of local immunogenesis, regeneration and phagocytosis, normalisation of urination, and increase of recurrence-free period.

6 tbl, 2 ex

FIELD: medicine, veterinary science, cosmetics.

SUBSTANCE: bioconcentrate is prepared from placenta by treatment of intact placenta of native structure with hydrophilic organic solvent at temperature 0-25oC for 3-8 h at M = 5-30. Bioconcentrate represents extract containing lipoprotein complex enriched with water-soluble and lipid-soluble vitamins and a solid residue containing glycolipoprotein including protein, polysaccharide, nucleoprotein and lipid components. Invention provides the development of the wasteless manufacturing bioconcentrate eliciting high stability at storage and high biological activity that allow expanding region in applying bioconcentrate and to develop the broad spectrum of medicinal and cosmetic formulations used in medicine, veterinary science and cosmetics. Invention can be used as an agent normalizing the metabolism in different organs and tissues and eliciting the reparative and anti-inflammatory effect.

EFFECT: improved preparing method, valuable medicinal properties of bioconcentrate.

1 tbl, 8 ex

Up!